Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study.

ABSTRACT:

Background

Infliximab (IFX) is effective in the treatment of inflammatory bowel disease; however, the effect is often not durable. It is unknown if proactive therapeutic concentration monitoring (TCM) of IFX improves outcomes.

Methods

This is a retrospective observational study examining the use of proactive TCM and titration of IFX to a target concentration for patients with inflammatory bowel disease in clinical remission at a tertiary care center. The primary aim was to describe the clinical course of patients who had proactive TCM. A secondary analysis was done to assess if this strategy was superior to the standard of care.

Results

Forty-eight patients were identified as having proactive TCM. Fifteen percent had an initial undetectable trough concentration. Twent

SUBMITTER: Vaughn BP 

PROVIDER: S-EPMC5557346 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature